The investigational drug BCD-220 is a reproduced pharmaceutical product (generic) currently in clinical development.
A reproduced (generic) drug product is a pharmaceutical preparation that contains the same active pharmaceutical ingredients (APIs), in the same qualitative and quantitative composition and dosage form as the reference drug product. Its bioequivalence to the reference product is demonstrated through appropriate bioavailability studies1.
The active ingredient of the investigational product is lenvatinib. The drug product is expected to exhibit antitumor properties and is intended for use in the treatment of various oncological diseases.
The mechanism of action involves selective inhibition of vascular endothelial growth factor receptors, as well as other receptors implicated in tumor progression.BCD-220 is one of BIOCAD’s drug products under clinical development.
- Decision No. 85 of the Eurasian Economic Commission's Council “On Approval of the Rules for Conducting Bioequivalence Studies of Medicinal Products within the Eurasian Economic Union” dated November 3, 2016.
This website section includes information about an investigational medicinal product for human use.